$IRD
Opus Genetics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is IRD up today? It is at $4.34 (+13.29%), and our scanner flagged it 52 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment IRD spikes, and full due diligence on IRD — key stats, earnings, dilution and insider activity. Free.
Get free $IRD alerts the moment volume spikes
Our scanner flagged $IRD 52 times in the last 30 days. Create a free account to track $IRD, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $4.34
- Change today
- +13.29%
- Previous close
- $3.83
- 52-week range
- $1.22 – $5.81
- Market cap
- $301M
- Institutional own.
- 71.75%
- Total held
- 73.9%
- Tradeable float
- 21.7M 26% of shares · after 2% insiders + 72% institutions
- Short interest
- 11.2M ▲ +4% vs prior · as of 2026-08-14
- Short % of float
- 51.8%
- Days to cover
- 15.3d
- Avg daily volume
- 774K
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- XNAS
- 5m
- 2.3x
- 15m
- 1.3x
- 1h
- 5.5x
- 1D
- 1.2x
Get free IRD + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $IRD up today?
IRD is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 8 unusual-volume and momentum alerts on IRD today, peaking at 2.3x its normal volume. A recent catalyst in the news: “Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences.” Early read: bullish.
Likely catalystOpus Genetics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingEFFECTRegistration declared effectiveAug 17, 2026 · 16 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
Insiders selling0 buys, 4 sells last 3 months (22/21 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Gagnon Robert E. Officer | Sold (automatic/other) | -8K | sold 1.3% | 584K | $23K at $2.95 | Jul 23, 26 |
Magrath George Officer | Sold (automatic/other) | -9K 0.01% of company | sold 0.5% | 1.73M | $28K at $2.95 | Jul 23, 26 |
Schachle Joseph K Officer | Sold (automatic/other) | -5K | sold 1.6% | 291K | $14K at $2.94 | Jul 23, 26 |
Yerxa Benjamin R Officer | Sold (automatic/other) | -7K | sold 1.0% | 704K | $22K at $2.97 | Jul 23, 26 |
Foundation Fighting Blindness Retinal Degeneration Fund Director | Sold (automatic/other) | -1.70M 2.0% of company | sold 31% | 3.79M | $7.4M at $4.35 | May 18, 26 |
Gagnon Robert E. Officer | Sold (automatic/other) | -8K | sold 1.3% | 592K | $41K at $5.18 | Apr 23, 26 |
Jayagopal Ashwath Officer | Sold (automatic/other) | -8K | sold 1.5% | 509K | $39K at $5.19 | Apr 23, 26 |
Magrath George Officer | Sold (automatic/other) | -10K 0.01% of company | sold 0.5% | 1.74M | $50K at $5.22 | Apr 23, 26 |
Zaremba Rabourn Amy Officer | Sold (automatic/other) | -2K | sold 0.9% | 189K | $9K at $5.20 | Apr 23, 26 |
Schachle Joseph K Officer | Sold (automatic/other) | -5K | sold 1.6% | 296K | $25K at $5.22 | Apr 23, 26 |
Yerxa Benjamin R Officer | Sold (automatic/other) | -7K | sold 1.0% | 712K | $39K at $5.24 | Apr 23, 26 |
Ainsworth Sean Director | Acquired (grant/award) | +24K 0.03% of company | added 8.2% | 322K | n/a | Apr 20, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $IRD runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 2,678,570 new shares · Priced at $4.48/share
- About $300.0M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$IRD Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$IRD Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to IRD
Comparable names in pharmaceutical preparations, closest in size first.
IRD stock FAQ
Why is $IRD up today?
IRD is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 8 unusual-volume and momentum alerts on IRD today, peaking at 2.3x its normal volume. A recent catalyst in the news: “Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences.” Early read: bullish.
What is the IRD stock price today?
IRD last traded at $4.34, up 13.29% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live IRD alerts?
The IRD Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged IRD 52 times in the last 30 days.
What exchange is IRD on?
IRD (Opus Genetics, Inc. Common Stock) trades on XNAS, with a market cap of about $301M in the PHARMACEUTICAL PREPARATIONS sector.
Is IRD good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge IRD for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.